

May 29, 2022 411563

To: TASE Members

Dear Sir/Madam,

Re: PURPLE BIOTECH LTD

A report regarding phase 1 interim monotherapy data for NT219 was published on EDGAR. The company stated that due to a technical failure, the report was not published in Israel. The report will be published immediately after resolving the failure.

Sincerely

(-)

Listing companies compliance unit